Related Experiment Videos
[Primary and secondary prevention in dyslipidemia in the elderly]
A Vogt1, R Nieczaj, H P Thomas
1Evangelisches Geriatriezentrum Berlin, Humboldt-Universität Berlin, Charité, Virchow-Klinikum, Berlin. anja.vogt@charite.de
Insights
Elderly individuals with cardiovascular disease (CVD) benefit from lipid-lowering therapy, particularly those aged 65-75, to reduce stroke risk and functional decline.
Area of Science:
- Geriatric Medicine
- Cardiology
- Pharmacology
Context:
- Cardiovascular disease (CVD) is a primary cause of mortality and disability in older adults.
- Atherosclerosis, a systemic disease, affects multiple vascular beds, including cerebral and peripheral arteries.
- Dyslipoproteinaemia is a key risk factor for atherosclerosis and cardiovascular events.
Purpose:
- To evaluate the benefits of lipid-lowering therapy in elderly patients with cardiovascular disease.
- To assess the impact of treating hypercholesterolaemia on stroke incidence and functional outcomes in older adults.
- To advocate for proactive screening and management of dyslipoproteinaemia in the elderly population.
Summary:
- Lipid-lowering therapy, particularly statins, can significantly decrease stroke incidence in elderly patients.
- Patients aged 65-75 with elevated LDL-cholesterol show substantial benefits from effective treatment.
- Effective cholesterol management in the elderly can prevent cardiovascular events, functional limitations, and disability.
Impact:
- Highlights the importance of geriatric assessment and risk stratification for tailoring lipid-lowering treatment regimens.
- Emphasizes that chronological age should not be a barrier to proven effective cardiovascular therapies.
- Supports the integration of lifestyle changes, nutritional therapy, and pharmacotherapy for managing dyslipoproteinaemia in older adults.
Abstract:
Cardiovascular disease (CVD) is the leading cause of mortality and a major cause of disability in advanced age. The relationship between coronary heart disease (CHD) and dyslipoproteinaemia is well known. The fact, however, that atherosclerosis is a systemic disease leads also to the consideration that patients suffering from cerebrovascular and peripheral arterial disease should benefit similarly from lipid lowering therapy as do patients with CHD. There is already growing evidence that the incidence of stroke may be markedly decreased by statin therapy. Though overall, the clinical significance of hypercholesterolaemia seems to decrease with increasing age, patients at age 65 to 75 tend to benefit even more than younger patients when elevated LDL-cholesterol is treated effectively. It should be noticed that prevention or postponement of cardiovascular events may also prevent premature functional limitations and disability in old age. Hence, it is suggested to screen elderly people with CVD for dyslipoproteinaemia and to treat elevated cholesterol levels by means of life style changes, nutritional therapy, and drug therapy. Treatment regimes should be considered depending upon complete risk stratification and geriatric assessment. Chronological age alone cannot be an argument to withhold a proven effective therapy from a growing segment of the population at risk.